Slingshot members are tracking this event:

MacroGenics and Merck announce a collaboration to evaluate the combination of MacroGenics' margetuximab, with Merck's pembrolizumab in a Phase 1b/2 clinical trial in patients with gastric cancer

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks



Additional Information

Management Comment "The combination of our proprietary Fc-optimized anti-HER2 antibody, with expected enhanced immune-mediated killing properties, and the anti-PD-1 antibody KEYTRUDA (pembrolizumab), is intended to exploit potentially complementary biology," said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. "Treatment options for patients with advanced HER2-positive gastric cancer are extremely limited. The combination of mechanisms engaged by margetuximab and KEYTRUDA could provide an important alternative for patients who do not respond to currently available regimens."
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 22, 2015
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Collaboration, Margetuximab, Pembrolizumab, Phase 1b/2 Trial, Gastric Cancer